Prosecution Insights
Last updated: November 04, 2026

Oyster Point Pharma Inc.

Technology area: Biotechnology & Pharmaceuticals

4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready • 2 patents granted in the last 365 days

Analysis

Oyster Point Pharma Inc. currently has 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. These actions are split among 3 distinct examiners and 3 distinct art units. NEAGU, IRINA is the busiest examiner, with 1 pending action assigned. The data shows that for the 3 pending office actions, there is no overlap in examiners or art units.

This distribution across 3 distinct examiners and 3 distinct art units implies that each patent application is being treated as an independent technical matter. Practitioners should note that the 3 pending office actions will likely follow different timelines and receive different types of rejections based on the 3 distinct art units involved. NEAGU, IRINA is one of three individuals currently shaping the company's pharmaceutical portfolio. The lack of concentration suggests that the company's current biotechnology efforts are technically diverse enough to trigger reviews from three separate specialized groups. Each of the 3 pending office actions requires a unique strategy.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

4
Total Pending OAs
3
Non-Final OAs
1
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

0
Overdue
0
Due this week
0
Due this month
0
Due in next 60 days
1
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

1
Hard (25%)
2
Medium (50%)
0
Easy (0%)
1
Unknown (25%)

Rejection Statute Mix

BucketCases
§103 only1 (25%)
Double-patenting + other1 (25%)
Multi-statute (no §101)1 (25%)
No statute on record1 (25%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

4
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

40 h
Manual time on pending OAs
8 h
Time saved (low, 20%)
14 h
Time saved (mid, 35%)
0.3 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
NEAGU, IRINA 1 46.8% +57.2%
ISMAIL, REHANA 1 75.5% +35.7%
VIVLEMORE, TRACY ANN 1 72.9% +6.6%
HAVLIN, ROBERT H 1 51.3% +28.3%

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18559512 AAV VIRION ENCODING NEUROTROPHIC FACTOR AND USES THEREOF VIVLEMORE, TRACY ANN —

Interview Candidates (3)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.

App #TitleExaminerDue in
18437748 SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-(PYRROLIDIN-3-YLVINYL)PYRIMIDINE ISMAIL, REHANA 70d
18825758 METHODS OF TREATING OCULAR CONDITIONS NEAGU, IRINA —
18049815 LOCAL ADMINISTRATION OF NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS FOR THE INHIBITION OF CORONAVIRUS INFECTIONS HAVLIN, ROBERT H —

Top Art Units

Art UnitApps
1629 1
1625 1
1638 1
1626 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18825758 METHODS OF TREATING OCULAR CONDITIONS NEAGU, IRINA 1629 §112DP Non-Final OA — Pending Sep 05, 2024
18437748 SYNTHESIS AND NOVEL SALT FORMS OF (R)-5-((E)-2-(PYRROLIDIN-3-YLVINYL)PYRIMIDINE ISMAIL, REHANA 1625 Other Non-Final OA 70d Pending Feb 09, 2024
18559512 AAV VIRION ENCODING NEUROTROPHIC FACTOR AND USES THEREOF VIVLEMORE, TRACY ANN 1638 §102§103§112 Non-Final OA — Pending Nov 07, 2023
18049815 LOCAL ADMINISTRATION OF NICOTINIC ACETYLCHOLINE RECEPTOR AGONISTS FOR THE INHIBITION OF CORONAVIRUS INFECTIONS HAVLIN, ROBERT H 1626 §103 Final Rejection — Pending Oct 26, 2022

Managing Oyster Point Pharma Inc.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does Oyster Point Pharma Inc. have?

Oyster Point Pharma Inc. has 4 pending office actions as of November 2026, spread across 4 art units and 4 examiners.

Which USPTO examiner handles the most Oyster Point Pharma Inc. applications?

Irina Neagu has the most, with 1 of Oyster Point Pharma Inc.'s pending office actions.

What technology area are Oyster Point Pharma Inc.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month